Professional Associations

This page includes news coverage of medical associations and medical societies. Use these links to find focused news coverage from specific organizations: Cardiology Associations, Healthcare Associations, Radiology Associations.

Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial
Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.
Deepak Bhatt discusses some of the most impactful trials at ACC 2026
Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science.
Impactful innovations reshape learning and technology at ACC.26
ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.
Cost-related medication non-adherence declined after the Inflation Reduction Act
Lower Medicare drug costs translated into more patients taking their medications, leading to better outcomes.
American College of Radiology elects new board leaders
Each of the members will assume their new role following the conclusion of ACR 2026, set to take place in Washington, D.C., in early May.

Prem Soman, MD, director of the Cardiac Amyloidosis Center and nuclear cardiology, and associate chief of cardiology at the University of Pittsburgh Medical Center Heart and Vascular Institute presented the late-breaking results from the long-term survival benefits and disease stabilization with the drug acoramidis in patients with transthyretin amyloid cardiomyopathy at ACC 2026.

Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial

Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.

To unpack the large number of lat-breaking trials at the American College of Cardiology 2026 meeting, Cardiovascular Business spoke in the above video interview with Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, director of the Mount Sinai Fuster Heart Hospital, who highlighted several studies he felt had the most scientific impact. This included a mix of drug, device and strategy trials pointing to advances in cardiology. #ACC #ACC26

Deepak Bhatt discusses some of the most impactful trials at ACC 2026

Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science.

Kathryn Berlacher, MD, MS, FACC, chair of the 2026 American College of Cardiology (ACC) 2026 Scientific Sessions, and clinical director of cardiology and a women's heart and cardio-obstetrics specialist at the University of Pittsburgh Medical Center, explains the major trend of artificial intelligence (AI) in cardiology, the use of coronary CT angiography (CCTA) for the first time at a medical meeting to scan attendees, and the rise in hands on, guideline, business and advocacy sessions.

Impactful innovations reshape learning and technology at ACC.26

ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.

Lower Medicare drug costs translated into more patients taking their medications, leading to better outcomes.

American College of Radiology elects new board leaders

Each of the members will assume their new role following the conclusion of ACR 2026, set to take place in Washington, D.C., in early May.

AI-powered EHR alerts make a world of difference for cardiologists, heart patients

AI can help care teams identify heart patients who would benefit from TAVR or another life-changing valve intervention.

Former American College of Cardiology president Hadley Wilson, MD, FACC, executive vice chair of Atrium Health's Sanger Heart and Vascular Institute, shared his thoughts on what he saw as the key studies in the above video interview with Cardiovascular Business. He covered numerous trials in more detail in the video. #ACC26 #ACC

Key clinical takeaways from ACC.26

Hadley Wilson, MD, a former American College of Cardiology president, spoke to Cardiovascular Business about several studies presented at ACC.26.

Michiel Voskuil, MD, PhD, an interventional cardiologist and professor at University Medical Center Utrecht in the Netherlands, presented his team’s data on the ACC.26 stage.

PCI before TAVR? In older CAD patients, deferral may be the best approach

Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.